Biological
Fresolimumab
Fresolimumab is a biological therapy with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Phase Distribution
Ph phase_2
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
NCT03064074
completedphase_1
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
NCT02581787
completedphase_2
Fresolimumab and Radiotherapy in Metastatic Breast Cancer
NCT01401062
completedphase_2
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT01665391
completedphase_1
Fresolimumab In Systemic Sclerosis
NCT01284322
Clinical Trials (5)
Showing 5 of 5 trials
NCT03064074Phase 1
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
NCT02581787Phase 1
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
NCT01401062Phase 2
Fresolimumab and Radiotherapy in Metastatic Breast Cancer
NCT01665391Phase 2
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT01284322Phase 1
Fresolimumab In Systemic Sclerosis
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5